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1012-131 Statins Decrease Mortality in Patients Undergoing 
Percutaneous Coronary Intervention With Left 
Ventricular Dysfunction
Michael J. Lipinski, Robert E. Martin, Michael J. Cowley, Evelyne Goudreau, Walter N. 
Malloy, George W. Vetrovec, Virginia Commonwealth University Health System, 
Richmond, VA
Background
While statins have been shown to decrease mortality in a population that went on to
develop heart failure after beginning statin therapy, uncertainty remains whether statins
are appropriate for patients with pre-existing left ventricular (LV) dysfunction. The goal of
this study was to determine whether statin therapy improved survival in patients with LV
dysfunction undergoing percutaneous coronary intervention (PCI).
Methods
We retrospectively evaluated consecutive patient procedures performed in our institution
from 1996 through 1999. To be included, patients had to have a technically adequate
angiographic LV gram with a calculated EF<50%. Patients with prior CABG were
excluded. Mortality data was retrieved using the United States Social Security Death
Index. Follow-up ranged from 3.5 to 6.5 years. 
Data Analysis
Cox Hazard regression, student T-tests, Kaplan-Meier survival analysis, and ROC curve
analysis was performed to compare mortality and variables between the different sub-
groups. Means are provided with ± Std Dev and p-values less than 0.05 were considered
significant.
Results 
A total of 244 patients with an average EF of 39% ± 9.8% fulfilled our criteria. Mean age
was 57.5 ±12 years, 68% were males, co-morbidities included 82% with HTN, 68% had
hypercholesterolemia, and 36% had DM. Sixty-one percent underwent PCI for a recent
MI, 68% percent of our population underwent PCI with stenting, and 64% were dis-
charged on statins. During follow-up, 27% of our population died. Of the patients taking
statins, 96% had hypercholesterolemia while 90% of patients with hypercholesterolemia
were taking statins. Statins significantly improved survival at 1, 3, and 5 years (97% vs
84%, p<.001; 93% vs 72%, p<.00001; 87% vs 63%, p<.00001). Statin survival benefits
persist regardless of MI history and EF. Statin use, along with age, calculated EF, diuretic
use, and renal disease, was found to be significant on Cox Hazard Regression.
Conclusion.
In our retrospective analysis on patients with left ventricular dysfunction undergoing PCI,
hypercholesterolemic patients discharged on statins had improved survival compared to
patients not taking statins with normal cholesterol levels.
1012-132 Atorvastatin Affects the Expression of Both 
Endothelium- and Liver-Derived Components of 
Thrombosis/Fibrinolysis System and Endothelial 
Function in Patients With Congestive Heart Failure
Dimitrios Tousoulis, Charalambos Antoniadis, Maria Kotsopoulou, Erini Bosinakou, 
Costas Tentolouris, Christos Pitsavos, Kyriakoula Marinou, Stella Brilli, Athanasios 
Trikas, Christodoulos Stefanadis, Athens University Medical School, Hippokration 
Hospital, Athens, Greece
Introduction: Congestive heart failure (CHF) is characterised by endothelial dysfunction
and increased thrombogenecity. We investigated the effect of atorvastatin on endothelial
function and on plasma levels of antithrombin III (ATIII), proteins C and S, factors V and
VII, von Willebrand factor (vWF), tissue plasminogen activator (tPA) and plasminogen
activator inhibitor 1 (PAI-1) in patients with CHF.
Methods: Thirty-five patients with CHF (NYHA II-IV) were randomized to receive atorv-
astatin 10mg/day (n=17) or no statin (n=18) for 4 weeks. Forearm blood flow was mea-
sured by venous occlusion strain-gauge plethysmography. Endothelium dependent
dilation (EDD) and endothelium independent dilation (EID) were expressed as the %
change of flow from baseline to the maximum flow during reactive hyperemia or after
sublingual nitroglycerin administration respectively. Plasma levels of thrombosis/fibrinoly-
sis components were determined with ELISA.
Results: Atorvastatin improved EDD (42.44±4.5 to 83.7±8.5%, p<0.01), decreased
plasma levels of tPA (15.5±2.2 to 12.3±1.6 ng/ml p<0.05), ATIII (82±3 to 74±4%, p<0.05),
prtC (88±6 to 64±6%, p<0.01), fV (126±8 to 95±7%, p<0.01) and PAI-1 (3.02±0.39 to
1.96±0.34 IU/L, p<0.05), while it did not affect EID (65±8 to 53±6% p=ns) and levels of
fVII (81±8 to 66±7% p=ns), vWF (135±13 to 123±19% p=ns) and prtS (93±5 to 95±8%
p=ns). EDD and EID remained unchanged in controls (from 48±5 and 67±8 to 45±5%
and 61±7% respectively p=ns for both). In control group, no significant change was
observed in levels of ATIII (85±4 to 88±3%,p=ns), prtC(84±6 to 84±5%,p=ns), fV(131±10
to 122±9%,p=ns), fVII(78±12 to 69±9%,p=ns), vWF (151±19 to 135±38%, p=ns), prtS
(100±8 to 96±6%, p=ns), tPA(13.2±1.5 to 11±2 ng/ml, p=ns) and PAI-1(2.64±0.38 to
3.25±0.34, p=ns).
Conclusions: Short-term treatment with atorvastatin improves endothelial function and
reduces plasma levels of tPA, PAI-1, antithrombin III, protein C and factor V, in patients
with CHF, suggesting that atorvastatin may affect the expression of both endothelium-
and liver-derived components of thrombosis fibrinolysis system, beyond its effect on vas-
cular endothelium in these patients.
1012-133 Statin Therapy Can Improve Cardiac Function and 
Survival After Heart Failure in Rats
Sahoko Ichihara, Akiko Noda, Akira Yamada, Tomoko Kato, Kohzo Nagata, Mitsunori 
Iwase, Toyoaki Murohara, Mitsuhiro Yokota, Nagoya University Graduate School of 
Medicine, Nagoya, Japan
Background: Congestive heart failure has been shown to be related to an increase in oxi-
dative stress. We hypothesized that statin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA
reductase, prevents the progression from compensated left ventricular (LV) hypertrophy
to heart failure and improves survival with a reduction in oxidative stress in a rat model.
Methods and Results: Dahl salt-sensitive (DS) rats fed an 8% NaCl diet from 7 weeks of
age were treated with pravastatin 50 mg/kg/day or 100 mg/kg/day from 7 or 12 weeks of
age. At 18 weeks of age, untreated DS rats exhibited prominent concentric LV hypertro-
phy, and diastolic and systolic dysfunction was seen by echocardiography. We found that
treatment with statin did not affect serum lipid levels or blood pressure. Treatment with
pravastatin 100 mg/kg/day (but not 50 mg/kg/day) from 7 weeks of age attenuated hyper-
tensive LV hypertrophy and markedly improved indices of diastolic function (peak nega-
tive myocardial velocity gradient); -2.25 ± 0.77/s to -3.28 ± 0.57/s, (p < 0.05) and systolic
function (LV fractional shortening); 28.5 ± 1.5% to 35.2 ± 1.2%, (p < 0.05), and also
improved survival rate (40.7% to 83.3%, p < 0.01). Treatment with statin ameliorated glu-
tathione redox status (p < 0.05) and improved inflammatory responses. We also found
that treatment with pravastatin (100 mg/kg/day only) from 12 weeks of age brought about
the same benefit for cardiac function and survival. Conclusion: Statin therapy before and
even after the development of hypertensive LV hypertrophy improved LV phenotypic
changes, diastolic and systolic function, and survival in a rat hypertensive heart failure
model.
1012-134 Direct, Dose-Dependent Antifibrotic Effects of 
Atorvastatin in Human Cardiac Fibroblast Cell Culture
Henry Krum, Jenny Martin, Rachel Denver, Salvatore Pepe, Monash University, NHMRC 
CCRE in Therapeutics, Melbourne, Victoria, 3004, Australia
Background: HMGcoA reductase inhibitors (statins) may have beneficial effects on car-
diac remodelling post myocardial injury. These effects appear to be additional to the lipid-
lowering and anti-ischaemic actions of these agents. As pathological deposition of extra-
cellular matrix (fibrosis) is a key component of remodelling post myocardial injury, we
sought to determine whether these agents could directly inhibit matrix production in-vitro,
as well as mechanisms by which these effects may occur.
Methods: The effect of atorvastatin (ATV, 10-8M-10-5M) was examined in human cardiac
fibroblast cell culture after stimulation with the known pro-fibrotic factors angiotensin II
(AII, 10-7 M) and transforming growth factor-β (TGF-β). Non-stimulated, non-treated wells
served as controls. Collagen production was estimated by [3H]-proline incorporation (P).
Results: AII and TGF-β increased [3H]-P by 38±17% and 90±34% respectively. ATV
caused a dose-dependent reduction in [3H]-P (% decrease c/f AII alone: 10-8M, -
44+19%; 10-7M, -44+14%; 10-6M, -55+14%; 10-5M, -78+13%; p<0.05; % decrease c/f
TGF-β alone: 10-8M, -9+4%; 10-7M, -20+12%; 10-6M, -46+6%; 10-5M, -67+15%; p<0.05).
ATV similarly reduced AII- and TGF-β-induced [3H]-P in a dose-dependent manner,
p<0.05. Both AII and TGF-β significantly increased α(1) pro-collagen mRNA by 22 and
300% respectively; an effect that was blocked by ATV (% decrease c/f. AII alone: 10-5M: -
54+23%; % decrease c/f TGF-β alone: 10-5M: -33±9.5%).
To determine whether these effects of statins were mediated by alterations in the pro-
fibrotic peptide, connective tissue growth factor (CTGF), we measured CTGF mRNA in
these studies. Both AII and TGF-β increased CTGF mRNA by 86±18% and 98±19%
respectively; this was significantly reduced by ATV (% decrease c/f AII alone: 10-5M: -
67%±18%; c/f TGF-β alone 10-5M: -44±13%).
Conclusions: We have demonstrated for the first time a direct, anti-fibrotic effect of
statins in human cardiac fibroblast cell culture, following stimulation with pro-fibrotic fac-
tors known to be important in cardiac remodelling post-myocardial injury. These actions
may contribute to the potential favourable anti-remodelling effects of statins.
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1013-113 Strain Rate and Strain Rate-Derived Time to Onset of 
Relaxation Can Be Used for the Early Detection of 
Impaired Myocardial Function in Asymptomatic Boys 
With Duchenne Muscular Dystrophy
Nickolaos D. Giatrakos, Maria Kinali, Francesco Muntoni, Petros Nihoyannopoulos, 
Hammersmith Hospital, NHLI, ICSM, London, United Kingdom, Dubowitz Neuromuscular 
Centre, Hammersmith Hospital, ICSM, London, United Kingdom
Background. Patients with Duchenne muscular dystrophy (DMD) frequently develop
dilated cardiomyopathy at the later stages of the disease. Strain rate (SR) has been used
to study ischeamia and cardiomyopathies and time to onset of regional relaxation (TR) by
SR imaging has been used to quantify regional myocardial function. The aim of this study
was to investigate the usefulness of SR and SR derived TR for the early detection of car-
diac involvement in young, asymptomatic patients with DMD which is critical to initiate
life-saving therapeutic interventions.
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Methods. Forty-five genetically characterised DMD boys (mean age 8.7±2.76 years)
were compared with 22 controls (mean age 9±2.96 years). All patients were without clin-
ical symptoms from the cardiovascular system and had normal conventional echocardio-
grams. We used the HDI 5000 (Philips Medical Systems) to acquire from the parasternal
long axis the colour M-mode tissue Doppler (TDI) of the posterior wall of the LV. Images
were digitally stored for offline analysis with dedicated software HDI-lab (Philips Medical
Systems). We calculated the SR using the formula SR=Ua-Ub/d where U the velocities of
the endocardium a and epicardium b, and d their distance at each time point. We defined
TR as the time from the R-wave of the ECG trace to the transition point of SR from posi-
tive to negative values. The TR values were corrected for the heart rate using the Bazett’s
formula and expressed in msec.
Results. There were no significant differences for the 2D and Doppler parameters from
the conventional echocardiographic studies of the two groups. SR in the DMD boys was
found to be significantly lower at systole (1,78±0,75s-1 vs. 2,82±0,5s-1, p<0,000) and
early diastole (-5,17±1,98s-1vs.-9,02±1,25s-1, p<0,000) but not at late diastole (-
1,52±0,84s-1vs.-1.6±0,46s-1, p<0,568). TRcorrected for the heart rate was found to be
higher in patients with DMD (384,47±40,12msec vs. 364,54±23,43msec), P<0.003.
Conclusion. SR measurements and SR TR were significantly different in asymptomatic
boys with DMD showing systolic and diastolic dysfunction at early stages and when con-
ventional echocardiographic studies are still normal.
1013-114 Improvement of Endothelial Function in Patients With 
Myocardial Inflammation by Angiotensin-Converting 
Enzyme Inhibition With Quinapril: A Randomized 
Double-Blind, Placebo Controlled Study
Katja B. Vallbracht, Uwe Kuehl, Peter L. Schwimmbeck, Bettina Seeberg, Heinz-Peter 
Schultheiss, Charite Medical University, Campus Benjamin Franklin Hospital, Berlin, 
Germany
Background
In patients with inflammatory cardiomyopathy (InfCM), immunohistological evaluation of
myocardial biopsies demonstrates an inflammatory response in myocardium and blood
vessels, which is associated with endothelial dysfunction. The aim of this study is to
investigate an improvement of inflammatory endothelial dysfunction by ACE-inhibition.
Methods
In 46 patients with suspected InfCM myocardial biopsies were obtained. They were ran-
domly assigned to treatment with quinapril (20-40 mg) or placebo for 6 months, double
blind. Endothelial function (ENF) was examined by high resolution ultrasound, measuring
flow mediated vasodilation (FMD) of the radial artery in response to reactive hyperemia
and endothelium independent vasoreactivity to glyceroltrinitrate, at the beginning of the
study and after 6 months.
Results
In 40 patients, myocardial inflammation (InfCM) was confirmed by immunohistology in
myocardial biopsies, 6 had normal myocardial biopsies. Mean age of the 18 male and 22
female patients was 43±12 years. In the quinapril-group (n=21), FMD increased signifi-
cantly from 3.34±2.78% at inclusion to 7.56±3.97% after 6 months (p<0.001). In the pla-
cebo-group (n=19), FMD decreased from 4.30±2.93% at inclusion to 3.53±2.41% after 6
months (p=0.287). GTN-MD was not changed significantly (25.75±9.1%). Mean EF
increased from 61.3±13.6% at inclusion to 64.3±9.4 after 6 months (p=0.040) in the
quinapril-group and from 56.2±18.6% to 59.7±15.6% (p=0.247) in the placebo-group. 20
patients had a second myocardial biopsy after 6 months, 11 in the placebo-group and 9
in the quinapril-group. All second biopsies showed persistent myocardial inflammation.
Conclusions
Endothelial dysfunction in patients with myocardial inflammation can be improved with
the ACE-inhibitor quinapril, as compared to placebo. This improvement is not due to elim-
ination of the myocardial inflammatory process or improvement of LV function. We con-
clude that ACE-inhibition directly improves endothelial dysfunction in patients with
myocardial inflammation.
1013-115 Familial Predisposition for Inflammatory 
Cardiomyopathy
Bernhard Maisch, Irene Portig, Andreas Wilke, Anette Richter, Volker Ruppert, Arsen D. 
Ristic, Guenther Hufnagel, Sabine Pankuweit, Philipps-University, Marburg, Germany
Introduction: Familial dilated cardiomyopathy (DCM) has been reported in the past. Fam-
ily screening identified DCM as an inherited disorder in up to 30%. Familial DCM (fDCM)
is phenotypically heterogeneous. Genetic and environmental factors may play pathoge-
netic roles. Since DCM results in some patients from chronic inflammation, we analysed
our Marburg DCM registry for familial inflammatory cardiomyopathy.
Methods: 208 consecutive index patients with inflammatory DCM were included in our
study (criteria: enlarged left ventricle (Henry Index ³ 117%), reduced ejection fraction
(<50%), histological evidence of an inflammatory infiltrate (³14 leucocytes / mm2 prefera-
bly activated T cells) in endomyocardial biopsies). Using a questionnaire, index patients
were selected for family studies comprising clinical examination, electrocardiography,
echocardiography, and blood sampling. Familial inflammatory DCM was diagnosed,
when at least one first degree relative met the criteria for DCM, died suddenly before the
age of 35, had pericardial effusion or both cardiac arrythmia and left ventricular dilatation.
Results: 8 index patients (4%) were identified. Mode of inheritence varied: autosomal
dominant in 4 families, autosomal or X-chromosomal dominant in 1, maternally inherited
in 1, autosomal dominant with skeletal muscle disease in 1, and with conduction defect in
1 family. Viral genome was undetectable in endomyocardial biopsies of all index patients.
Conclusion: Inflammatory DCM should be considered an independent disease entity, the
etiology of which is yet to be established. Genetic predisposition to viral/autoimmune
mechansims may be of importance. In our patients predisposition to autoimmune myo-
carditis was found exclusively.
1013-116 Impact of Left Ventricular Remodeling Upon Ventricular 
Ectopic Activity in Patients With Preserved Systolic 
Function
Jason A. Mitchell, Richard V. Milani, Carl J. Lavie, Frank H. Messerli, Ochsner Clinic 
Foundation, New Orleans, LA
Background: LVH by ECG criteria is associated with ectopic density, increased rates of
complex ventricular ectopy, and ultimately sudden cardiac death (SCD). Although we and
others have demonstrated that early LV concentric remodeling (CR) is associated with
increased morbid CV events and mortality, the association between CR and complex
ventricular ectopic activity (VEA) has not been studied.
We sought to evaluate the effect of LV structure on VEA and mortality from a combined
echocardiographic and holter database of 4,601 patients with preserved LV function (EF
> 50%).
Using published criteria utilizing relative wall thickness (RWT), and LV mass index
(LVMI), we classified patients as normal (normal RWT and LVMI), CR (increased RWT,
normal LVMI), concentric hypertrophy (CH) (increased RWT and increased LVMI) and
eccentric hypertrophy (EH) (normal RWT, increased LVMI). (*p<0.05) 
Patients with hypertrophy had a mortality rate 3 times that of normals. Although patients
with CR had the lowest rate of VEA, their mortality was double that of normals.
Conclusion: LV hypertrophy, particularly EH, is associated with increased VEA and mor-
tality among patients with normal EF, supporting increased SCD in this population. CR
revealed the lowest VEA, but is associated with more than twice the mortality of patients
with normal LV geometry suggesting a non-electrical cause of death.
1013-117 HIV Cardiomyopathy Is Rare in the Era of Highly Active 
Antiretroviral Therapy
Neil W. Siecke, Keyvan Jahanbakhsh, Thomas Waltman, Ori Ben-Yehuda, University of 
California, San Diego, San Diego, CA
Background: HIV Cardiomyopathy remains poorly understood, with limited data on its
incidence in the era of highly active anti-retroviral therapy.
Methods: Retrospective chart review of all HIV+ patients seen at the UCSD HIV Clinic
who had an echocardiogram (TTE) during 2001-2003. Control population of all subjects
with TTEs during the same period.
Results: 244/2849 (8.5%) HIV patients had a TTE and 19 subjects had moderate to
severe LV dysfunction (8% of HIV + subjects with a TTE; 0.7% of HIV + population).
Compared with 12,283 control patients, HIV+ subjects were younger (46 vs. 60 p <
0.001) and had a slightly lower average ejection fraction (EF) (58.1% vs 59.9%, p = 0.02)
but a trend towards fewer subjects with EF < 45% (9% vs 14%, p=0.06) . There was no
correlation between the EF and the most recent or lowest CD4 count or viral load. There
was no association between LV dysfunction and CMV infection, testosterone deficiency,
malnutrition, or HIV encephalopathy. All 19 HIV+ patients with moderate or severe LV
dysfunction had a plausible reason for depressed LV function; CAD in all 10 patients over
age 50; alcohol abuse (3), adriamycin use (1), polysubstance abuse (3), and active sep-
sis (2) in those under 50.
Conclusions: The incidence of LV dysfunction was similar in HIV + and non-infected
persons referred for TTE. HIV+ patients with LV dysfunction had traditional risk factors for
LV dysfunction; there was no correlation with the severity of HIV infection, or conditions
associated with HIV infection, and LV dysfunction. 
LV Geometry Number Mean PVC’s/hour Mean VT runs/24h Mortality(%)
Normal 2189 35.4 0.46 1.7
CR 1333 26.6* 0.07* 4.2*
CH 309 38.4* 0.24* 5.7*
EH 261 47.5* 3.5* 5.2*
HIV Status vs. EF less than 45%
EF Less than 45% Total
EF > 45% EF < 45%
HIV Status HIV Positive 203
(90.6%)
21
(9.4%)
224
(100%)
Control 9464
(86.3%)
1507
(13.7%)
10971
(100%)
Total 9667
(86.3%)
1528
(13.7%)
11195
(100%)
p=0.06 by Chi Square
